A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Condition:   Prostate Cancer Intervention:   Drug: MBM-02 (Tempol) Sponsor:   Matrix Biomed, Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 4 June 2020Source: Journal of EthnopharmacologyAuthor(s): Tuhanguli Tuoheti, Hafiz Abdul Rasheed, Ling Meng, Ming sheng Dong
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: In spite of young population, less exposure to environmental risk factors and high rate of racial mixing, the early PCa diagnosis is still a challenge in FG. The observed incidence and mortality rates suggest underestimation of PCa cases and too late specific care what is also suggested by adverse pathological and biological characteristics of the tumors at the time of diagnosis. LEVEL OF EVIDENCE: 3. PMID: 32493660 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
ConclusionsThe results suggest that BPH may be associated with the development of fibrosis and gland atrophy within the peripheral zone. As 80% of prostate cancer originates from the glandular epithelium within the peripheral zone, this observed phenomenon may explain the inverse relationship between BPH and incidence of prostate cancer well documented in the literature.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Condition:   Metastatic Castration-Resistant Prostate Cancer Interventions:   Drug: Lu-PSMA;   Drug: Enzalutamide Sponsors:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   National Health and Medical Research Council, Clinical Trials Centre;   Prostate Cancer Research Alliance;   Endocyte;   Astellas Pharma Inc;   Australian Nuclear Science and Technology Organisation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
By AMY E. KRAMBECK, MD With the exceptions of pediatrics and obstetrics/gynecology, women make up fewer than half of all medical specialists. Representation is lowest in orthopedics (8%), followed by my own specialty, urology (12%). I can testify that the numbers are changing in urology – women are up from just 8% in 2015, and the breakdown in our residency program here at Indiana University is now about 20% of the 5-year program. One reason for the increase is likely the growth of women in medicine – 60% of doctors under 35 are women, as are more than half of medical school enrollees. I also credit a...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Amy Krambeck female physicians majority male specialties Patients Source Type: blogs
CONCLUSIONS: Circular RNA_LARP4 could suppress cell migration and invasion of PCa by upregulating FOXO3A. PMID: 32495863 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Prostate cancer (PCa) represents one of the most common types of cancers facing the male population. Nowadays, to confirm PCa, systematic or multiparametric MRI-targeted transrectal or transperineal biopsies o...
Source: EJNMMI Physics - Category: Radiology Authors: Tags: Original research Source Type: research
In order to limit radiotherapy (RT)-related side effects, effective toxicity prediction and assessment schemes are essential. In recent years, the growing interest toward artificial intelligence and machine learning (ML) within the science community has led to the implementation of innovative tools in RT. Several researchers have demonstrated the high performance of ML-based models in predicting toxicity, but the application of these approaches in clinics is still lagging, partly due to their low interpretability. Therefore, an overview of contemporary research is needed in order to familiarize practitioners with common me...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a critical component of new approaches to combat this disease. The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically translated approaches to detect, characterize, and treat disease in this rapidly expanding field.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsMaximal reduction of the rectal dose seems very important to prevent serious rectal hemorrhage. In addition, we should consider the risk of rectal toxicities in patients with abnormalities in the rectal mucosa, especially hemorrhoids.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Research